SCHEMBL20499757

SCHEMBL20499757

CC(C)Oc1cc(Cl)c2c(c1Cl)C(=O)NCC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 5/20 0.43
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ NOTUM Q6P988 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ PTK2B Q14289 1/20 0.35
▸ DAPK3 O43293 1/20 0.33
▸ DYRK3 O43781 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ PIM1 P11309 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ CSNK1A1 P48729 1/20 0.33
▸ CLK2 P49760 1/20 0.33
▸ GSK3A P49840 1/20 0.33
▸ GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15815035 0.88 KDM4E (0.36) EZH2KDM4EALDH1A1POLBHPGD
SCHEMBL15830735 0.84 KDM4E (0.36) EZH2KDM4EALDH1A1POLBHPGD
SCHEMBL15814278 0.84 NCOA1 (0.43) KDM4EALDH1A1HPGDNOTUMHTT
SCHEMBL15814409 0.82 EED (0.36) EZH2KDM4EALDH1A1POLBHPGD
SCHEMBL15815050 0.81 EED (0.35) EZH2KDM4EALDH1A1POLBHPGD
SCHEMBL16821944 0.78 EZH2 (0.31) EZH2KDM4EALDH1A1POLBHPGD
SCHEMBL15830727 0.77 P2RX3 (0.37) EZH2PARP1
SCHEMBL20499628 0.77 EZH2 (0.45) EZH2KDM4EALDH1A1POLBHPGD
SCHEMBL15814178 0.75 NCOA1 (0.41) KDM4EALDH1A1HPGDHTTPTK2B
SCHEMBL15830723 0.75 PARP10 (0.44) KDM4EALDH1A1NOTUMHTTPTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266542-B2 EZH2 inhibitors Mirati Therapeutics, Inc. (US) 2019-04-23 — — US disclosed
US-10266542-B2 EZH2 inhibitors Mirati Therapeutics, Inc. (US) 2019-04-23 — — US disclosed
US-20180265517-A1 EZH2 Inhibitors Mirati Therapeutics, Inc. 2018-09-20 — — US disclosed
US-9255104-B2 Cyclopropyl modulators of P2Y12 receptor AUSPEX PHARMACEUTICALS, INC. (US) 2016-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180265517-A1 EZH2 Inhibitors EZH2, BMI1, EED EZH2 1/4885KDM4E 27/4885ALDH1A1 1969/4885
US-10266542-B2 EZH2 inhibitors EZH2, BMI1, EED EZH2 1/4885KDM4E 27/4885ALDH1A1 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback